1. Home
  2. PWP vs EYPT Comparison

PWP vs EYPT Comparison

Compare PWP & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perella Weinberg Partners

PWP

Perella Weinberg Partners

HOLD

Current Price

$21.60

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$15.05

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PWP
EYPT
Founded
2006
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
PWP
EYPT
Price
$21.60
$15.05
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$23.50
$31.80
AVG Volume (30 Days)
758.0K
813.4K
Earning Date
05-01-2026
05-06-2026
Dividend Yield
1.30%
N/A
EPS Growth
138.52
N/A
EPS
0.47
N/A
Revenue
N/A
$7,539,000.00
Revenue This Year
$31.87
N/A
Revenue Next Year
$16.54
$3,115.57
P/E Ratio
$45.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.59
$5.46
52 Week High
$25.93
$19.11

Technical Indicators

Market Signals
Indicator
PWP
EYPT
Relative Strength Index (RSI) 73.99 59.39
Support Level $20.70 $14.50
Resistance Level $23.01 $18.99
Average True Range (ATR) 0.87 0.64
MACD 0.40 0.26
Stochastic Oscillator 78.79 91.22

Price Performance

Historical Comparison
PWP
EYPT

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: